A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

Por Burris, Howard, Ansell, Stephen, Neumanitis, John, Weiss, Geoffrey, Sikic, Branimir, Northfelt, Donald, Pilja, Lana, Davis, Thomas, Yellin, Michael, Keler, Tibor, Bullock, Timothy
Publicado em 2013

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

Por Ansell, Stephen, Northfelt, Donald, Flinn, Ian, Burris, Howard, Dinner, Shira, Villalobos, Victor, Sikic, Branimir, Pilja, Lana, Yellin, Michael, Keler, Tibor, Davis, Thomas
Publicado em 2013

Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity

Por Bullock, Timothy, McClintic, Hillary, Jeong, Se, Smith, Kelly, Olson, Walt, Ramakrishna, Venky, Vitale, Laura, Green, Jennifer, Yellin, Michael, Davis, Thomas, Keler, Tibor
Publicado no J Immunother Cancer (2014)

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

Por Sarnaik, Amod A., Yu, Bin, Yu, Daohai, Morelli, Dawn, Hall, MacLean, Bogle, Dilip, Yan, Lulu, Targan, Stephan, Solomon, Jolie, Nichol, Geoff, Yellin, Michael, Weber, Jeffrey S.
Publicado em 2010

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

Por Mayer, Lloyd, Sandborn, William J, Stepanov, Yuriy, Geboes, Karel, Hardi, Robert, Yellin, Michael, Tao, Xiaolu, Xu, Li An, Salter-Cid, Luisa, Gujrathi, Sheila, Aranda, Richard, Luo, Allison Y
Publicado em 2014

IT-28 VACCINATION AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III IN GLIOBLASTOMA: THE RINDOPEPIMUT COMPASSIONATE USE EXPERIENCE

Por Razis, Evangelia, Vlahovic, Gordana, Recht, Lawrence, Wheeler, Helen, Reardon, David, Fisher, Paul G., Owen, Scott, Nicholas, Kelly, Paradise, Elsa, Yellin, Michael, Davis, Thomas, Weller, Michael, Stupp, Roger, Hottinger, Andreas F.
Publicado em 2014

IT-30 ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA

Por Reardon, David, Schuster, James, Tran, David, Fink, Karen, Nabors, Louis, Li, Gordon, Lukas, Rimas, Desjardins, Annick, Ashby, Lynn, Duic, J. Paul, Aneiro, Lynn, Hawthorne, Thomas, Green, Jennifer, Yellin, Michael, Davis, Thomas, Sampson, John
Publicado em 2014

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Por Maker, Ajay V., Phan, Giao Q., Attia, Peter, Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Haworth, Leah R., Levy, Catherine, Kleiner, David, Mavroukakis, Sharon A., Yellin, Michael, Rosenberg, Steven A.
Publicado em 2005

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

Por Maker, Ajay V., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Hughes, Marybeth, Yellin, Michael J., Haworth, Leah R., Levy, Catherine, Allen, Tamika, Mavroukakis, Sharon A., Attia, Peter, Rosenberg, Steven A.
Publicado em 2006

Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers

Por Anandasabapathy, Niroshana, Breton, Gaëlle, Hurley, Arlene, Caskey, Marina, Trumpfheller, Christine, Sarma, Popi, Pring, James, Pack, Maggi, Buckley, Noreen, Matei, Irina, Lyden, David, Green, Jennifer, Hawthorne, Thomas, Marsh, Henry C., Yellin, Michael, Davis, Thomas, Keler, Tibor, Schlesinger, Sarah J.
Publicado no Bone Marrow Transplant (2015)

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Por Beck, Kimberly E., Blansfield, Joseph A., Tran, Khoi Q., Feldman, Andrew L., Hughes, Marybeth S., Royal, Richard E., Kammula, Udai S., Topalian, Suzanne L., Sherry, Richard M., Kleiner, David, Quezado, Martha, Lowy, Israel, Yellin, Michael, Rosenberg, Steven A., Yang, James C.
Publicado em 2006

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Por Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.
Publicado em 2005

IMCT-08 ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA

Por Reardon, David A., Desjardins, Annick, Schuster, James, Tran, David D., Fink, Karen L., Nabors, Louis B., Li, Gordon, Bota, Daniela A., Lukas, Rimas V., Ashby, Lynn S., Duic, J. Paul, Mrugala, Maciej M., Werner, Andrea, Vitale, Laura, He, Yi, Green, Jennifer, Yellin, Michael J., Turner, Christopher D., Davis, Thomas A., Sampson, John H.
Publicado no Neuro Oncol (2015)

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Por Hodi, F. Stephen, O’Day, Steven J., McDermott, David F., Weber, Robert W., Sosman, Jeffrey A., Haanen, John B., Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C., Akerley, Wallace, van den Eertwegh, Alfons J.M., Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M., Linette, Gerald P., Hogg, David, Ottensmeier, Christian H., Lebbé, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I., Wolchok, Jedd D., Weber, Jeffrey S., Tian, Jason, Yellin, Michael J., Nichol, Geoffrey M., Hoos, Axel, Urba, Walter J.
Publicado em 2010